Public Alert No. 037/2026 – Alert on Suspected Counterfeit Pulmicort® (Budesonide) Inhalation Suspension

The National Agency for Food and Drug Administration and Control (NAFDAC) in Nigeria has issued a public alert regarding the detection of a suspected counterfeit Pulmicort® (Budesonide) Inhalation Suspension in the Nigerian market. The alert was triggered by information provided to NAFDAC by AstraZeneca, the manufacturer of the genuine product, following their market surveillance activities. This development highlights the ongoing challenge of counterfeiting in the pharmaceutical industry and underscores the need for vigilance among regulatory agencies and consumers alike.

The detection of a suspected counterfeit Pulmicort® (Budesonide) Inhalation Suspension in Nigeria has significant implications for public health and safety. The alert issued by NAFDAC serves as a critical reminder of the importance of ensuring the authenticity of medicinal products in circulation. As a key regulatory agency, NAFDAC plays a crucial role in protecting consumers from substandard or falsified medicines. This article will examine the background to this development, its legal significance, and the potential implications for stakeholders.

The National Agency for Food and Drug Administration and Control (NAFDAC) is responsible for regulating and supervising the manufacture, importation, exportation, distribution, sale, and use of food, drugs, cosmetics, medical devices, and packaged water in Nigeria. In carrying out its mandate, NAFDAC conducts regular market surveillance activities to detect and prevent the circulation of counterfeit or substandard products. The alert on suspected counterfeit Pulmicort® (Budesonide) Inhalation Suspension is a testament to NAFDAC's commitment to protecting public health and safety.

The potential consequences of this development are significant. If confirmed, the presence of counterfeit Pulmicort® (Budesonide) Inhalation Suspension in the Nigerian market could lead to adverse health outcomes for consumers who use the product. Furthermore, the detection of a suspected counterfeit product raises concerns about the integrity of the supply chain and the effectiveness of regulatory oversight.

In conclusion, the detection of a suspected counterfeit Pulmicort® (Budesonide) Inhalation Suspension in Nigeria highlights the ongoing challenge of counterfeiting in the pharmaceutical industry. Regulatory agencies like NAFDAC must continue to play a critical role in protecting public health and safety by ensuring that only genuine medicinal products are available in the market.